Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126369671 | 12636967 | 1 | I | 20160727 | 20160809 | 20160809 | EXP | JP-PFIZER INC-2016365631 | PFIZER | SHINODA, Y.. POTENTIAL DRUG INTERACTION BETWEEN PACLITAXEL AND CLOPIDOGREL. BIOMEDICAL REPORTS. 2016;5 (1):141-145 | 65.00 | YR | F | Y | 0.00000 | 20160809 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126369671 | 12636967 | 1 | PS | PACLITAXEL. | PACLITAXEL | 1 | 80 MG/M2, WEEKLY (132.8 MG/WEEK, TOTAL TIMES ADMINISTRATION: 15) | U | 76131 | 80 | MG/M**2 | /wk | |||||||
| 126369671 | 12636967 | 2 | I | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 75 MG, DAILY | U | 0 | 75 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126369671 | 12636967 | 1 | Ovarian cancer |
| 126369671 | 12636967 | 2 | Angina pectoris |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126369671 | 12636967 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126369671 | 12636967 | Drug interaction | |
| 126369671 | 12636967 | Leukopenia | |
| 126369671 | 12636967 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |